U.S. markets closed

Cell MedX Corp. (CMXC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2450+0.0230 (+10.36%)
At close: 3:50PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2220
Open0.2220
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2210 - 0.2450
52 Week Range0.2010 - 0.7990
Volume17,085
Avg. Volume59,352
Market Cap14.55M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0130
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ChromaDex to Present at Oppenheimer 31st Annual Healthcare Conference
    Business Wire

    ChromaDex to Present at Oppenheimer 31st Annual Healthcare Conference

    ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:50pm ET (12:50pm PT).

  • ChromaDex Appoints Preventative Medicine Specialist Dr. David L. Katz to its Scientific Advisory Board
    Business Wire

    ChromaDex Appoints Preventative Medicine Specialist Dr. David L. Katz to its Scientific Advisory Board

    ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed David L. Katz, MD, MPH, FACPM, FACP, FACLM - CEO of Diet ID, Inc, founder and former director of Yale University’s Yale-Griffin Prevention Research Center and past president of the American College of Lifestyle Medicine, to its Scientific Advisory Board (SAB). Dr. Katz is a leading expert in nutrition, health promotion and the prevention of chronic disease through his work as a researcher, author and clinician.

  • New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients
    Business Wire

    New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients

    ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study "Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19" were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving mitochondrial function, the protocol included nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate.